Moderna, Inc. $MRNA Shares Newly Acquired by Alta Advisers Ltd

Alta Advisers Ltd purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,755 shares of the company’s stock, valued at approximately $531,000.

A number of other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Moderna during the 2nd quarter worth about $2,142,877,000. Theleme Partners LLP bought a new position in Moderna in the 2nd quarter worth $564,272,000. Wellington Management Group LLP boosted its stake in Moderna by 4.4% during the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after purchasing an additional 103,977 shares during the last quarter. Merck & Co. Inc. bought a new stake in Moderna during the second quarter valued at about $161,642,545. Finally, Bamco Inc. NY purchased a new position in shares of Moderna during the second quarter valued at approximately $139,317,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Up 5.3%

MRNA stock opened at $254.19 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna, Inc. has a one year low of $22.28 and a one year high of $267.50. The firm’s fifty day moving average is $191.85 and its 200 day moving average is $91.51.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($1.10) by $1.48. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. Moderna’s revenue was up 29.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.51) EPS. On average, sell-side analysts forecast that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MRNA has been the topic of several research analyst reports. Sanford C. Bernstein restated a “market perform” rating on shares of Moderna in a report on Friday, September 25th. CLSA upgraded shares of Moderna to an “outperform” rating in a report on Friday, August 28th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $130.00 price objective on shares of Moderna in a research note on Wednesday, August 19th. Evercore upped their price target on shares of Moderna from $50.00 to $80.00 in a report on Thursday, October 8th. Finally, Argus upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research note on Friday, August 28th. Six equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, Moderna presently has an average rating of “Hold” and an average target price of $107.10.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of $1.31 billion, up 29.2% year over year, and earnings of $0.38 per share, far ahead of analysts’ expectations for a loss. Stronger overseas COVID-19 vaccine sales helped drive the results. Reuters report on revenue and demand
• Positive Sentiment: Management raised its 2026 revenue-growth forecast to 15%–25%, from a prior outlook of up to 10%. The company also said it plans to reduce research and development spending, supporting its near-term financial performance. CNBC outlook report
• Positive Sentiment: Health Canada authorized Moderna’s seasonal flu and flu-COVID combination vaccines for adults 50 and older, opening a potential new market for its mRNA products. CBC report on Canadian approvals
• Positive Sentiment: Investors are also watching prospects for Moderna’s cancer vaccine: CEO Stéphane Bancel said it could have potential beyond melanoma. That adds pipeline excitement, though future commercial value remains uncertain. Yahoo Finance report on cancer vaccine prospects
• Neutral Sentiment: Moderna and GSK settled a patent dispute involving Moderna’s COVID and RSV shots. The settlement removes a source of legal uncertainty, but the available report does not specify its financial terms. Reuters report on patent settlement
• Negative Sentiment: The sharp rally has heightened concerns that expectations for the cancer-vaccine pipeline may be running ahead of near-term revenue potential. Moderna’s longer-term prospects still depend on sustaining vaccine sales and turning pipeline advances into commercial products. Barron’s analysis of Moderna’s earnings and valuation

Insider Transactions at Moderna

In other Moderna news, President Stephen Hoge sold 40,294 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the sale, the president directly owned 1,525,858 shares in the company, valued at approximately $219,921,913.54. This trade represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 197,251 shares of company stock valued at $33,875,904. Insiders own 10.80% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.